SCHEMBL14320587

SCHEMBL14320587

COc1ccc(Nc2nc(-c3ccc(N4CCCC4)nc3)nc3cn[nH]c23)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 10/20 0.46
ABCB1 P08183 7/20 0.46
ABCC1 P33527 4/20 0.46
ZAP70 P43403 3/20 0.45
BRD4 O60885 1/20 0.42
SYK P43405 4/20 0.41
JAK2 O60674 1/20 0.41
PRKD3 O94806 1/20 0.40
EGFR P00533 1/20 0.40
PRKCG P05129 1/20 0.40
PRKCB P05771 1/20 0.40
LCK P06239 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCH P24723 1/20 0.40
PRKCI P41743 1/20 0.40
PRKCE Q02156 1/20 0.40
PRKCQ Q04759 1/20 0.40
PRKCZ Q05513 1/20 0.40
PRKCD Q05655 1/20 0.40
PRKD1 Q15139 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320291 0.85 SYK (0.51) ABCG2ABCB1ABCC1BRD4SYK
SCHEMBL14320369 0.84 ABCG2 (0.62) ABCG2ABCB1ABCC1MAPT
SCHEMBL14320522 0.84 SYK (0.50) SYKJAK2EGFR
SCHEMBL13734546 0.84 ROCK2 (0.45) SYKEGFRROCK2ROCK1
SCHEMBL14320428 0.84 SYK (0.49) SYKJAK2
SCHEMBL14320461 0.83 KDM1A (0.45) SYKJAK2MAPT
SCHEMBL14320305 0.81 SYK (0.51) SYKJAK2PRKD3EGFRLCK
SCHEMBL14321350 0.81 ABCG2 (0.65) ABCG2ABCB1ABCC1SYKMAPT
SCHEMBL14321014 0.81 ABCG2 (0.57) ABCG2ABCB1ABCC1MAPT
SCHEMBL14320384 0.80 SYK (0.56) SYKJAK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ABCG2 3810/4885ABCB1 4019/4885ABCC1 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.